With 13% annual earnings growth forecast and 45% under ‘fair value’, should I buy more of this FTSE giant now?
AstraZeneca (LSE:â¯AZN) remains one of the FTSEâs most structurally reliable long-term value creators, in my view. Its robust, cashâgenerative earnings,...
